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This paper describes the design and methodology of the
participating cohorts in the EUROSTROKE project.
Information is given about the cohort sampling, its size,
the follow up procedures and event classification.
Information is also given about the measurement of the
cardiovascular and cerebrovascular risk factors in each
of the cohorts separately. The cohorts described are the
Caerphilly study in Cardiff, United Kingdom; the Kuopio
Ischaemic Heart disease study in Kuopio, Finland; the
Portugal study in Coimbra, Portugal; the EPIC cohort in
Athens, Greece; the Ilsa study from Firenze, Italy; the
Rotterdam Study in Rotterdam, the Netherlands, and the
Novosibirsk cohort in Novosibirsk, Russia.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
EUROSTROKE is a collaborative study amongEuropean research centres to investigate thevariation in incidence of fatal and non-fatal
ischaemic and haemorrhagic stroke among popu-
lations in different European countries and to
evaluate whether the observed differences in
stroke incidence across countries can be ex-
plained by differences in prevalence of estab-
lished cardiovascular risk factors and to study the
relative importance of smoking and some selected
dietary factors (potassium intake, alcohol con-
sumption), haemostatic disturbances (fibrino-
gen) and comorbidity (rheumatic heart disease,
atrial fibrillation) compared with established risk
factors as determinants of the occurrence of
ischaemic and haemorrhagic stroke (fig 1).1 The
EUROSTROKE database is drawn from ongoing
European population-based prospective follow up
studies (cohorts) and is designed as a case-
control study nested within these ongoing stud-
ies. For each stroke case, two controls were
sampled. Controls were matched on day of
baseline examination only. Apart from its objec-
tives, the EUROSTROKE database allows for
aetiological analyses looking into various risk
factors for stroke. EUROSTROKE formally started
on 1 January 1994. At present, data on stroke and
risk factors of four cohorts were available for
analyses.
As EUROSTROKE is based on ongoing cohort
studies, information on cardiovascular risk factors
in each of the participating centres was already
being collected before the EUROSTROKE project
was established. Whenever possible, an exhaustive
attempt was made to further harmonise the
collected information to make comparison across
studies possible. Nevertheless, baseline measure-
ments could not be standardised beyond the
attempts done in each individual study a priori.
This paper describes the individual cohorts in
detail (table 1).
DESCRIPTION OF THE COHORTS
Cardiff, United Kingdom
The British contribution to EUROSTROKE comes
from the Caerphilly Heart Disease study in Wales,
United Kingdom, in which 2512 men, aged 45 to
59 years are participating.2 Baseline examinations
took place from 1979 to 1983. Follow up
examinations were performed from 1984 to 1988
(phase II) and from 1989 to 1993 (phase III).
Stroke events were registered through national
mortality statistics, hospital discharge records,
self report and family report. Of the registered
events, additional information on signs and
symptoms, on neuroimaging, necropsy and a copy
of the discharge records were collected. When
complete, stroke cases were submitted for review
to the EUROSTROKE case review board. Recently,
100 stroke events had been submitted for review
and 200 controls subjects had been drawn from
the remaining cohort. Eighty four stroke cases
were classified as definite/probable stroke by the
EUROSTROKE review board; those were contrib-
uted to the EUROSTROKE database.
Information on smoking, alcohol consump-
tion, and medical history was obtained by
questionnaire. The subject’s smoking behaviour
was categorised into current, former or never.
Alcohol consumption was categorised into cur-
rent drinkers and non-current drinkers (former
and never). In addition, an estimate of grams of
alcohol per day was obtained. Presence of
diabetes mellitus was based on the question: “Do
you suffer from diabetes mellitus?”. Information
on a history of stroke was obtained by direct
questioning at baseline: “Did you ever suffer from
a stroke?”. A similar approach was taken for
myocardial infarction. Presence of angina pectoris
was based on either the cardiovascular Rose
questionnaire or direct questioning. Systolic and
diastolic blood pressure were measured once at
one occasion in sitting position. Height and
weight were measured and body mass index (kg/
m2) was calculated. An electrocardiogram was
made and the presence of atrial fibrillation and of
a Q-wave myocardial infarction and left ventricu-
lar hypertrophy were assessed according to the
Minnesota classification system. Left ventricular
hypertrophy was assessed according to the
Minnesota classification system (codes 3.1, 3.3,
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3.4).3 A fasting blood sample was taken for determination of
serum lipids (total cholesterol, HDL cholesterol). Serum total
cholesterol level was determined with an automatic analyser
using enzymatic procedures.4 Fibrinogen was measured
according to the nephelometrical method.
In the Caerphilly Study a self administered, semi-
quantitative 56 item food frequency questionnaire was given
to each participant for completion, with help from his partner,
at home. In addition, after receiving instructions by nutrion-
ists, a representative subsample (3 in 10) was asked to
complete a weighed seven day record. Food intake was
estimated from the food frequency questionnaire by multiply-
ing the frequency of consumption by average portion size and
nutrient intake was calculated.5
Kuopio, Finland
The Finnish contribution to EUROSTROKE comes from the
Kuopio Ischaemic Heart Disease Risk Factor study, which is a
population-based prospective cohort study comprised of an age
stratified random sample of 2682 men aged 42, 48, 54 and 60
years. The baseline examination was performed between 1984
and 1989.6 Fatal and non-fatal stroke cases were collected
through the national mortality statistics and the FINMONICA
stroke registries. Stroke was defined according to FINMONICA
criteria and definitions.7 Case ascertainment from the baseline
examination to 1 January 1993 revealed 74 stroke cases. Control
subjects (n=148) were randomly drawn from the cohort that
remained free from stroke during follow up.
Information on smoking, alcohol consumption, and medial
history was obtained by questionnaire. The subject’s smoking
behaviour was categorised into current, former or never. Alco-
hol consumption was categorised into current drinkers and
non-current drinkers (former and never). In addition, an esti-
mate of grams of alcohol per day was obtained. Presence of
diabetes mellitus was based on the question: “Do you suffer
from diabetes mellitus?”. Information on a history of stroke
was obtained by direct questioning at baseline: “Did you ever
suffer from a stroke?” A similar approach was taken for myo-
cardial infarction. Presence of angina pectoris was based on
either the cardiovascular Rose questionnaire or direct ques-
tioning.
Systolic and diastolic blood pressure were measured twice
at one occasion in sitting position. Height and weight were
measured and body mass index (kg/m2) was calculated. An
electrocardiogram was made and the presence of atrial fibril-
lation and of a Q-wave myocardial infarction and left
ventricular hypertrophy were assessed according to the
Minnesota classification system. Left ventricular hypertrophy
was assessed according to the Minnesota classification system
(codes 3.1, 3.3, 3.4). A fasting blood sample was taken for
determination of serum lipids (total cholesterol, HDL choles-
terol). Serum total cholesterol level was determined with an
automatic analyser using enzymatic procedures. Fibrinogen
was measured according to the Von Clauss method.8
In the Kuopio Ischaemic Heart Disease Risk factor study the
consumption of food was assessed at time of blood sampling
with an instructed and interview checked four day food
recording by household measures, as described elsewhere.9
The nutrient intake was estimated using the Nutrica compu-
ter program for calculation of nutrient intake.
Figure 1 EUROSTROKE: Schematic
presentation of the approach to
answer the three study objectives.
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Table 1 Information on sampling frame, sampling method, sample size and procedures for follow up for each of the
participating centres
Country Site
Principal
investigator
Sample
frame Sample method
Sample
size Follow up design
Finland Kuopio J T Salonen General
population
Age stratified random sample of
men, aged 42, 48, 54 and 60 years
2682 National mortality registry
Stroke registry
Helsinki J Tuomilehto General
population
Random sample around 15000 National mortality registry
Stroke registry
Greece Athens A Trichopoulou General
population
Men and women volunteers, 30–75
years
28577 National mortality registry
Active follow up
Italy Firenze D Inzitari General
population
Age stratified random sample men
and women, aged 65–84 years
4373 Hospital-based stroke registry
Follow up by questionnaire,
telephone and re-examination
Netherlands Rotterdam D E Grobbee General
population
Random sample of men and women,
aged 55 years or over
7983 National mortality registry
P J Koudstaal General Practitioner Stroke
Registry
Portugal Coimbra A Freire Concalves General
population
Random sample of men and women,
aged 55 years or over
3020 General Practitioner based
stroke registry
Russia Novosibirsk Y Nikitin General
population
Random sample of men and women,
aged 25 to 64 years
9006 Stroke Registry (MONICA
procedures)
United Kingdom Cardiff P C Elwood General
population
Random sample of men, aged
45–59 years
2512 National mortality registry
Hospital records
Follow up by questionnaire
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Athens, Greece
The Greek contribution to EUROSTROKE comprises data from
the Greek component of the European Prospective Investiga-
tion into Cancer and nutrition (EPIC).10 The EPIC study is a
large prospective study, aiming at the investigation of the role
of nutrition and related factors on the aetiology of cancer and
other chronic diseases. The study is being carried out in nine
European countries, under the coordination of the Inter-
national Agency for Cancer Research (IARC) with the support
of the “Europe Against Cancer Program” of the European
Union combined with national and IARC resources.
In Greece, EPIC is being carried out by the Department of
Hygiene and Epidemiology of the University of Athens Medi-
cal School, in collaboration with the Department of Nutrition
and Biochemistry of the National School of Public Health and
the Greek Society of Nutrition and Foods. The Greek cohort
consists of 28 577 volunteers, men and women aged 30–75
years, residing in urban and rural areas from all over Greece.
Recruitment was completed in March 1999 and the follow up
of study subjects started in January 1997. The follow up will
last for approximately 10 years and it will be conducted at two
year intervals from the date of recruitment.
Information on medical history, lifestyle and environmental
factors is provided by the study participants, by means of an
interview, conducted by trained personnel. All data are
recorded in standardised questionnaires. History of stroke,
rheumatic heart disease, myocardial infarction, angina pec-
toris, diabetes mellitus and hypertension is recorded. Family
history of stroke and myocardial infarction, socioeconomic
indices, such as educational level and occupation, as well as
history of tobacco smoking and physical activity, are also
recorded. Dietary intake, supplementation and alcohol con-
sumption are assessed via a validated semi-quantitative food
frequency questionnaire administered by trained interviewers.
Anthropometric indices like height, weight, waist and hip
circumferences are measured using standardised procedures.
Arterial blood pressure is measured twice, with the use of a
mercury sphygmomanometer. All drugs consumed the week
before recruitment (especially type and quality of hyper-
tension treatment), are recorded and coded according to the
criteria of the Anatomical Therapeutic Chemical (ATC) classi-
fication index of medications. Finally, a non-fasting venipunc-
ture is performed. Blood samples are stored in liquid nitrogen
containers for future analyses.
Active follow up is implemented in the Greek centre. Record
linkage with the National Death Registration System is not
possible because of confidentiality reasons. Therefore, fatal
stroke cases are being ascertained actively, by tracing the
death certificates in regional mortality registries. In addition,
fatal cases are verified through medical records and necropsy
reports (whenever performed). Coding of fatal strokes is done
according to the 10th revision of the International Classifi-
cation of Diseases. With respect to non-fatal stroke cases,
efforts are made to achieve the highest level of confirmation.
A stroke case ascertainment questionnaire has been devel-
oped, collecting information on signs, symptoms (location,
onset, duration), laboratory findings and treatment. Hospital
discharge diagnoses are recorded and copies of reports of
computed tomography, magnetic resonance imaging, angi-
ograms, or lumbar punctures are being collected, whenever
possible. In case of non-hospitalisation, information is
obtained by contacting the treating physician. All stroke cases,
especially the non-hospitalised ones, will be evaluated by a
neurologist and subsequently submitted for review to the
EUROSTROKE review board.
The Greek EPIC centre has provided data on cerebrovascu-
lar risk factor profiles (gender, age, systolic blood pressure,
antihypertensive treatment, pulse rate, current smoking,
history of stroke, myocardial infarction, angina pectoris,
diabetes mellitus, height, weight, body mass index) for a sam-
ple of the study population. This sample consists of the 2659
participants recruited during 1994.
ILSA study, Italy
The Italian contribution to EUROSTROKE arises from the
Italian Longitudinal Study on Ageing (ILSA). ILSA is a
population-based,multicentre prospective cohort study focus-
ing at normal aging and aging disease and its determinants.
The ILSA is described in detail elsewhere.11 In short the ILSA
is aimed at the evaluation of age related functional changes of
cardiovascular, endocrine and nervous systems, and at the
estimation, in a cohort of older Italians, of prevalence and
incidence rates of the following age associated diseases:
angina pectoris, myocardial infarction, cardiac arrhythmia,
congestive heart failure, hypertension, peripheral artery
disease, diabetes, stroke, dementia, parkinsonism and distal
symmetric neuropathies. A random sample of 5632 people
aged 65–84 years, free dwelling or institutionalised, stratified
by age and gender, was extracted from the demographic lists
in eight Italian municipalities: Genoa, Segrate (Milan),
Selvazzano-Rubano (Padua), Impruneta (Florence), Fermo
(Ascoli Piceno), Naples, Casamassima (Bari), and Catania.
Following the equal allocation strategy, 88 subjects of each
gender were included in four age groups (65–69, 70–74, 75–79,
80–84 years) in every participating centre, yielding the overall
study sample.
The ILSA design includes both cross sectional and longitu-
dinal components. At the baseline survey, cases were
identified through a two phase design. In the screening phase
(phase 1), involving all the participants in the sample, a
personal interview was conducted to determine demographic
characteristics and work category, and to collect information
on functional conditions, risk factors and diseases symptoms;
a physical examination, carried out by a general physician, and
laboratory investigations including haematology tests, spiro-
metry, electrocardiography and retinography were performed.
Data on anthropometry and nutrition were also collected. In
phase 2 a specialist (geriatrician or neurologist, according to
the different conditions) confirmed, through a visit and
review of medical records, disease diagnoses in suspected
cases.
The reliability of the diagnostic process was assured by the
following methods: (1) interviewers, general physicians, neu-
rologists and geriatricians were centrally trained and certified
in data collection and form completion procedures; (2) site
visits to all participating centres were performed during the
data collection phase by members of the Coordinating Unit
located in Florence, in order to supervise the field work, step
by step, and to discuss potential problems with the staff mem-
bers of each centre; (3) the overall diagnostic process was cen-
trally reviewed by a panel of experts for each disease. The cross
sectional survey was carried out between March 1992 and
June 1993 (prevalence day: 1 March 1992).
According to the ILSA methodology, the screening of
suspected stroke cases was based on a comprehensive home
interview, performed by trained lay personnel using a
structured questionnaire, and on a simple neurological exam-
ination made by the general physician. The questionnaire
contained: (1) a simple question: have you ever had a diagno-
sis of stroke or cerebral haemorrhage?, and, independently
from this one, (2) questions about previous symptoms: have
you ever had for more than 24 hours: (a) speech disturbances;
(b) hemifacial palsy or twisted mouth; (c) limb weakness or
Key points
• Differences in stroke mortality across European countries
are impressive.
• Explanation of these differences is important: incidence or
case fatality.
• EUROSTROKE aims at explaining differences in stroke mor-
tality, using data from existing cohorts in Europe.
i4 Bots, Elwood, Nikitin, et al
www.jech.com
 on 20 November 2006 jech.bmj.comDownloaded from 
paralysis? Subjects answering “yes” to any of the four
questions were invited for phase 2 examination. If the subject
was unable to cooperate in the interview, for example, because
of cognitive impairment, information was gathered from a
proxy responder.With a simple neurological examination gait,
limbs tone and power, tendon reflexes, touch and pain sensa-
tion were evaluated. Subjects presenting with a deficit in limbs
power were also invited for further examination.
Subjects screened as possible stroke cases were visited by a
neurologist who, in a detailed and standardised fashion,
inquired about symptoms, evaluated gait, speech and lan-
guage, cranial nerves, limbs tone and power, tendon reflexes,
cerebellar function and sensation, and reviewed medical
records. According to the World Health Organisation, stroke
was defined as “rapidly developing clinical signs of focal or
global disturbance of cerebral function, with symptoms
lasting for more than 24 hours or leading to death, with no
apparent cause other than of vascular origin”. Both first ever
and recurrent strokes were considered, while transient
ischaemic episodes were not taken into account. Date of
stroke, initial symptoms and signs, vascular risk factors, hos-
pital admission, laboratory investigations, treatment, and cur-
rent level of disability were registered. Information on subjects
refusing phase 2 examination as well as on subjects dead
between phase 1 and phase 2 was gathered by interviewing
general practitioners (GP), and reviewing medical records.
Follow up examination of the ILSA participants started on
September 1995. Participants were re-examined following the
same procedures used at the baseline examination. Briefly, the
case identification strategy consisted of a screening phase,
administered by lay interviewers to all participants, and a
clinical assessment of those who screened positive, carried out
by specialists (neurologists and geriatricians), to make the
final diagnoses. During this second cross sectional survey, for
every deceased individual, medical information was gathered
from both the subject’s GP and relatives, using ad hoc
questionnaires.
Moreover, two years after the baseline survey the overall study
population had been followed up by telephone interview to
determine the vital status and hospitalisation. Information
regarding people who either had died or were unable to
answer the interview had been gathered from both GP and
relatives. A clinical investigator in each study centre inter-
viewed the GP of every deceased subject about the possible
occurrence of a stroke before death. Information about drug
prescriptions, other diseases, hospitalisation, and institution-
alisation was also gathered from GP as well as from subject’s
relatives. Hospital discharge diagnoses and death certificate
diagnoses were reviewed for each hospitalised or deceased
subject.
Coimbra, Portugal
The Portugese contribution to EUROSTROKE is based on a
single centre prospective follow up study in a population ran-
dom sample of 3020 people of 50 years or over living in the
district of Coimbra; Coimbra Incidence Stroke Study . Baseline
data were collected from November to December 1996 by local
general practitioners.
Medical history was taken according to a EUROSTROKE
standard questionnaire and physical and laboratory measure-
ments were made. Hypertension was diagnosed if present in
medical records, if the patient was under specific antihyper-
tensive medication or if a systolic blood pressure equal to 160
mm Hg or over or a diastolic blood pressure of 95 mm Hg or
over was present in two measurements in the sitting position
separated by a few minutes. Previous history of transient
ischaemic attack or stroke was assessed by questionnaire and
by analysis of clinical records. Angina pectoris as well as myo-
cardial infarction were also assessed at baseline according to
history and records on GPs files. The same procedure was
adopted to investigate family history of stroke or myocardial
infarction. Rheumatic fever was assessed by inquiry and
review of medical records. Diabetes mellitus was diagnosed if
subjects currently take oral antidiabetics or insulin. Current,
former and never smoker was the classification of the smoking
status. A similar classification was used for alcohol consump-
tion and quantification was expressed in grams per day.
Drinking pattern was recorded. Weight, height, waist and hip
circumference were measured. An ECG was made and the
diagnosis of arrhythmia, Q-wave myocardial infarction, and
left ventricular hypertrophy was registered if present. A
fasting venepuncture was performed to assess serum lipids,
packed cell volume, γ-GT, platelets, white blood cells and lym-
phocytes. These laboratory procedures were dismissed if simi-
lar laboratory analysis from the past six months were
available.
The methodology of case finding is based mainly on the
information obtained from the GPs. Subjects and close family
members are requested to inform personal family doctor if any
event occur.
Transient ischaemic attack is defined as an acute loss of
focal cerebral or vision function with symptoms lasting less
than 24 hours and which after adequate investigation is
presumed to be attributable to embolic or thrombotic vascular
disease. Stroke is defined according to the WHO criteria as
rapidly developing clinical signs of focal or global loss of
cerebral function, with symptoms lasting more than 24 hours
or leading to death, with no apparent cause other than that of
vascular origin.
As soon as identified by GPs the incident fatal and non-fatal
events information is immediately sent to our centre in the
University Hospital of Coimbra to confirm the nature of the
event. Confirmation is made by neurologists participating in
the study by analysis of medical history or hospital discharge
records or direct examination. Classification of stroke sub-
types is made, when possible, with information obtained from
imaging investigation. Regular mailings to GPs are sent every
year to inquire about possible events not previously detected.
Death certificates of all the patients dying during the study are
centrally reviewed. Stroke events will be submitted for review
to the EUROSTROKE Review board.
Rotterdam, the Netherlands
The Dutch contribution to EUROSTROKE comes from the
Rotterdam Study, which is a population-based prospective fol-
low up study among 7983 subjects, aged 55 years or over, liv-
ing in the suburb of Ommoord in Rotterdam, the
Netherlands.12 Baseline data were collected from March 1990
to July 1993. In the Rotterdam Study, information on incident
fatal and non-fatal events is obtained from the GPs working in
the study district of Ommoord as described earlier.13 The GPs
involved report all possible cases of stroke to the Rotterdam
research centre. Events are presented in coded information
following the International Classification of Primary Care
(ICPC).14 With respect to the vital status of the participants,
information is obtained at regular intervals from the munici-
pal authorities in Rotterdam and also death of a participant is
reported by GPs.
When an event or death has been reported, additional
information is obtained by interviewing the GP and scrutinis-
ing information from hospital discharge records in case of
admittance or referral. All suspected cerebrovascular events
reported by the GPs were submitted for review to the EUROS-
TROKE case review board. From baseline to December 1994,
192 stroke cases were identified and submitted for review and
a total of 384 control subjects were drawn from the remainder
of the cohort that remained free from stroke during follow up.
A total of 157 events were classified as definite or probable
strokes.
Information on smoking, alcohol consumption, and medial
history was obtained by questionnaire. The subject’s smoking
EUROSTROKE participants i5
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behaviour was categorised into current, former or never. Alco-
hol consumption was categorised into current drinkers and
non-current drinkers (former and never). In addition, an esti-
mate of grams of alcohol per day was obtained. Presence of
diabetes mellitus was considered present when subjects used
blood sugar lowering drugs. Information on a history of stroke
was obtained by direct questioning at baseline: “Did you ever
suffer from a stroke?”. A similar approach was taken for myo-
cardial infarction. Presence of angina pectoris was based on
either the cardiovascular Rose questionnaire or direct
questioning.
Systolic and diastolic blood pressure were measured twice
at one occasion in sitting position. Height and weight were
measured and body mass index (kg/m2) was calculated. An
electrocardiogram was made and the presence of atrial fibril-
lation and of a Q-wave myocardial infarction was assessed by
using the automated diagnostic classification system of the
Modular Electrocardiogram Analysis System (MEANS).15 Left
ventricular hypertrophy diagnosis was assessed on the
parameters voltage, shape and repolarisation, as detailed
elsewhere.15 16 A non-fasting blood sample was taken for
determination of serum lipids (total cholesterol, HDL choles-
terol). Serum total cholesterol level was determined with an
automatic analyser using enzymatic procedures in
Rotterdam.17
Fibrinogen levels were derived from the clotting curve of
the prothrombin time assay using Thromborel S as reagent on
an Automated Coagulation Laboratory.15 The latter method
correlates well with the Von Clauss method.18
Dietary intake was assessed with a 170 item semi-
quantitative food frequency questionnaire, which is a modi-
fied version of a previously validated questionnaire19 as
described in detail elsewhere.20 The questionnaire was admin-
istered in two ways. In the first stage at the home of the
participant, participants checked off foods they usually ate (at
least twice a month) in the past year. The second stage at the
research centre, a dietitian asked the participants how much
and how often each food item was consumed. Furthermore,
the questionnaire was thoroughly checked. Average daily
dietary nutrient intake was calculated by multiplying the
frequency and amount consumed for each food item by its
nutrient content listed in an automated version of the Dutch
Food Composition Table.21
Novosibirsk, Russia
The Russian contribution to EUROSTROKE comes from stud-
ies performed in the Octyabrsky, the Kirovsky and Leninsky
districts of Novosibirsk, Siberia. The Novosibirsk cohort is
based on three population-based surveys, that were conducted
between 1984 and 1989 as part of the WHO MONICA
project.23 The Novosibirsk cohort comprises 9006 men and
women aged 25 to 64 years. Stroke cases were collected
through a specifically developed stroke registry, aiming to
identify fatal and non-fatal hospitalised and non-hospitalised
stroke patients.23 24 Stroke events were defined according to
MONICA criteria and definitions.25 From baseline to December
1995, a total of 100 stroke cases had been identified and 200
control subjects were drawn from the database. Finally, 79
subjects proved to be true strokes.
Information on smoking, alcohol consumption, and medial
history was obtained by questionnaire. The subject’s smoking
behaviour was categorised into current, former or never. Alco-
hol consumption was categorised into current drinkers and
non-current drinkers (former and never). In addition, an esti-
mate of grams of alcohol per day was obtained. Presence of
diabetes mellitus was not determined. Information on a
history of stroke was obtained by direct questioning at
baseline: “Did you ever suffer from a stroke?”. A similar
approach was taken for myocardial infarction. Presence of
angina pectoris was based on either the cardiovascular Rose
questionnaire or direct questioning.
Systolic and diastolic blood pressure were measured twice
at one occasion in sitting position. Height and weight were
measured and body mass index (kg/m2) was calculated. An
electrocardiogram was made and the presence of atrial fibril-
lation and of a Q-wave myocardial infarction and left
ventricular hypertrophy were assessed according to the
Minnesota classification system. A fasting blood sample was
taken for determination of serum lipids (total cholesterol,
HDL cholesterol). Serum total cholesterol level was deter-
mined with an automatic analyser using enzymatic
procedures.26 Fibrinogen was not measured.
EUROSTROKE CASE REVIEW BOARD
The review board comprised of four Dutch neurologists. Based
on all information, including symptoms and signs obtained by
interviewing the GP or, in case of hospital referral, hospital
data, the neurologists classified the events as definite,
probable and possible stroke. Events were classified by two
neurologists. In case of disagreement a third neurologist was
consulted, whose opinion was decisive for the final classifi-
cation. The present analysis is restricted to definite and prob-
able events, outcomes in which a stroke most probably did
occur according to the neurologist’s opinion. For the present
analysis an incident stroke was considered to have occurred
when (1) the event had led to a hospitalisation and the hospi-
tal discharge record indicated a diagnosis of a new stroke. The
clinical diagnosis was based on signs and symptoms, and
neuroimaging investigations during hospital stay (definite
stroke); or (2) in case of no hospitalisation, signs and
symptoms associated with the event obtained from the
general practitioner records and interview were highly
suggestive of a stroke according to the neurologists (probable
stroke) or (3) in case of out hospital death, when the general
practitioners reported that the cause of death was a cerebrov-
ascular accident and a cardiac cause was judged by the general
practitioner to be highly unlikely (probable stroke).
The event was classified into first and recurrent stroke and
into subarachnoid haemorrhage, intracranial haemorrhage,
intracerebral infarction, and unspecified (not documented).
For the non-MONICA centres (the Netherlands, United King-
dom) ischaemic stroke was further classified into lacunar inf-
arct; total anterior circulation infarct; partial anterior circula-
tion infarct; posterior circulation infarct and unspecified
infarct (undocumented). The classification was made follow-
ing the guidelines described by Bamford and coworkers27 and
by the European Atrial Fibrillation Trial.28
General data analytical approach
The association between risk factor and stroke was evaluated
using logistic regression techniques. For continuous variables
like blood pressure or fibrinogen, generally analyses were per-
formed using the risk factor as a continuous variable (per unit
or standard deviation increase). Additional analyses were per-
formed in quintiles or quartiles of the risk factor distribution
as observed among controls. When the distribution of the risk
factor differed considerably across centres, like in dietary
intake, a Z score approach was being applied. Analyses were
first performed within each centre. In the pooled analyses in
which information of all centres was combined, each
individual was categorised into the quartile based on the cen-
tre specific risk factor distribution. Adjustments were made
for those variables that were related to both stroke risk and
risk factor level, and not assumed to be an intermediate factor
in the causal relation between risk factor and stroke
occurrence. Whether the associations differed across centres,
or between subgroups of patients, like diabetics or smokers,
multiplicative interactions terms were used.
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Separate analyses were usually performed for total stroke,
fatal and non-fatal stroke, cerebral infarction and haemor-
rhagic stroke, and when possible for subtypes of cerebral inf-
arction. Results are usually expressed as odds ratios with cor-
responding 95% confidence limits.
DISCUSSION
The description of the cohorts shows that across cohorts
differences will exists in case ascertainment methods and in
risk factor measurements. These difference may lead to bias in
the association under study. Appropriate analytic approach
will be to used to limit the possible biases. The approaches will
be described in move detail in each paper where it is appropri-
ate.
In summary, this paper describes the design and method-
ology of the participating cohorts in the EUROSTROKE
project. Information is given about the cohort sampling, its
size, the follow up procedures and event classification. Also
information is given about the measurement of the cardiovas-
cular and cerebrovascular risk factors in each of the cohorts
separately.
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